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Research  report
Transcriptional  signatures  of  brain  aging  and  Alzheimer’s  disease:
What  are  our  rodent  models  telling  us?
Kendra  E  Hargis,  Eric  M  Blalock ∗
University of Kentucky College of Medicine, Department of Pharmacology and Nutritional Science, Lexington, KY, United States
h  i  g  h  l  i g  h  t  s
• Published  brain aging  and  Alzheimer’s  disease  (AD)  transcriptomes  are  studied.
• Human  and rodent  brain  aging  profiles  are  similar.
• Human  AD  is  highly  consistent  across  studies.
• Transgenic  AD mouse  models  are  not  similar  to  one  another  or to  human  AD.
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a  b  s  t  r  a  c  t
Aging  is  the  biggest  risk  factor  for  idiopathic  Alzheimer’s  disease  (AD).  Recently,  the National  Institutes  of
Health  released  AD research  recommendations  that include:  appreciating  normal  brain  aging,  expanding
data-driven  research,  using  open-access  resources,  and  evaluating  experimental  reproducibility.  Tran-
scriptome  data  sets  for aging  and  AD in  humans  and animal  models  are  available  in NIH-curated,  publically
accessible  databases.  However,  little work  has been  done  to  test  for  concordance  among  those  molecular
signatures.  Here,  we  test  the  hypothesis  that  brain  transcriptional  profiles  from  animal  models  recapit-
ulate  those  observed  in the  human  condition.  Raw  transcriptional  profile  data  from  twenty-nine  studies
were  analyzed  to produce  p-values  and fold  changes  for  young  vs. aged  or control  vs.  AD conditions.  Con-
cordance  across  profiles  was  assessed  at three  levels:  (1)  #  of  significant  genes observed  vs. #  expected
by  chance;  (2) proportion  of  significant  genes  showing  directional  agreement;  (3) correlation  among
studies  for  magnitude  of effect  among  significant  genes.  The  highest  concordance  was  found  within  sub-
jects across  brain  regions.  Normal  brain  aging  was  concordant  across  studies,  brain  regions,  and  species,
despite  profound  differences  in  chronological  aging  among  humans,  rats  and  mice.  Human  studies  of
idiopathic  AD were  concordant  across  brain  structures  and  studies,  but  were  not  concordant  with  the
transcriptional  profiles  of  transgenic  AD  mouse  models.  Further,  the  five  transgenic  AD mouse  models
that  were  assessed  were  not  concordant  with  one  another.  These  results  suggest  that  normal  brain  aging
is similar  in  humans  and  research  animals,  and  that  different  transgenic  AD model  mice  may  reflect
selected  aspects  of  AD  pathology.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Idiopathic Alzheimer’s disease (AD), already the most prevalent
form of age-related dementia, is becoming a proportionally greater
risk as other dementia rates decrease due to improved cardio- and
neuro-vascular health [1]. Aging is the single most influential risk
Abbreviations: AD, Alzheimer’s disease; CA, cornu ammonus of hippocampus;
DG, dentate gyrus; EC, entorhinal cortex; FC, frontal cortex; FDR, false discovery
rate; GEO, gene expression omnibus; PFC, prefrontal cortex; TG, transgenic.
∗ Corresponding author.
E-mail address: emblal@uky.edu (E.M. Blalock).
factor for the development of idiopathic AD and the US Census
Bureau projects that 20% of the US population will be ≥65 years
of age by 2030, up from just 10% in the year 2000 [2,3]. This dis-
proportionate expansion of the aging population is projected to
result in increased AD prevalence. It is estimated that the number
of Americans with AD will increase from ∼4 million in 2000–7.7
million in 2030 and to almost 15 million by 2050 [4]. Despite clear
evidence of the profound influence aging has on susceptibility to
AD, little basic research using animal models has focused on this
interplay.
Although basic research animals, like humans, show age-related
changes in cognition [5–8], most non-human species do not
http://dx.doi.org/10.1016/j.bbr.2016.05.007
0166-4328/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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Fig. 1. Assessing similarity/concordance across transcriptional profiles. A. When contrasting studies, method 1 (False Positive) assesses the number of genes expected to be
significant due to the error of multiple testing. Total number of genes common to both studies multiplied by the p-value cutoffs used in both studies to identify significant
genes  (e.g., 13146 total genes * 0.01 for hippocampal (hip) * 0.01 for entorhinal cortex (EC) yields 131 genes expected in each study with 1 gene common between them.
Method  2 (post hoc) uses the number of genes observed to be significant in each study, divided by the total number of genes tested, to establish the probability that any
gene  randomly drawn from the data set would be significant. The number in the overlap is predicted by the product of the post hoc probabilities for each direction in each
study.  In the Berchtold et al., 2008 hippocampal profile, 358 genes were significantly downregulated and 962 were significantly upregulated. In the same study’s entorhinal
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develop AD-like pathology unless induced to do so experimen-
tally. By far the most common animal models of AD are transgenic
mice. These animals develop symptoms consistent with human
AD. Unfortunately, interventions that reduce or prevent pathology
in transgenic mouse models have met  with limited success when
translated back to human AD [9]. As the search for a successful AD
treatment intensifies, U.S. funding agencies such as the NIH are urg-
ing basic researchers to consider research designs that appreciate
AD in the context of an aging brain phenotype. More broadly, the
NIH has recently published new guidelines for experimental rigor,
reproducibility, and transparency across all studies. This, at least in
part, is due to high-impact publications projecting that fifteen to
fifty percent of published research is not replicable [10–12]. This
lack of replication is laid at the feet of reporting bias, poor experi-
mental design, and/or inadequate description of procedures. These
issues cast doubt not only on the translatability of basic research
in aging and AD, but indeed, on the reliability of the initial findings
themselves.
As a step toward evaluating replicability and translational rel-
evance across the brain aging and Alzheimer’s disease studies,
transcriptional profiling data was incorporated into a meta-
analysis. Transcriptional profiles were selected because they have
less bias, more detailed experimental design descriptions, and raw
data archived in publically available databases [13,14]. Profiles of
normal aging in rats [15–18], mice [19,20], and humans [21–24]
were selected. For AD comparison, idiopathic human AD [25–29],
human Down’s syndrome [30] (as a human genetically induced
model of AD-like pathology), as well five transgenic mouse AD mod-
els (Alzforum naming conventions): J20 (PDGF-APPSw,Ind) [31],
Tg2576 [32], 3xTg [29], 5xFAD [33], and CK-p25 [34], were selected.
Raw data were downloaded, re-annotated, and re-analyzed.
Similarity across transcriptional profiles was assessed at three lev-
els: (1) the number of genes observed to be commonly significant
vs. those expected to be significant by chance; (2) the propor-
tion of significant genes that showed directional agreement among
studies; and (3) the correlation in magnitude of change among
commonly significant genes. Agreement was strongest when com-
paring different brain regions from the same subjects, regardless of
species or treatment. Human and rodent models of aging showed
consistent results, with a strongly concordant cross-species upreg-
ulation of hippocampal immune/inflammatory signaling. Similarly,
human hippocampal AD signatures were highly concordant, but
in contrast to normal aging, revealed predominately downregu-
lated gene expression associated with neuronal and mitochondrial
processes. Among mouse models: J20, Tg2576 and 3xTg profiles
showed poor concordance with any other profile, while 5xFAD and
CK-p25 did show moderate agreement with one another, and with
human AD among upregulated genes.
These results indicate a common human brain aging signa-
ture composed primarily of upregulated immune and vascular
signaling that is well-modeled in rodent aging. Similarly, human
idiopathic AD brain signatures are highly concordant with one
another, but dramatically different from the aging signature, being
primarily comprised of downregulated mitochondrial and neuronal
signatures. However, transgenic mouse models of AD, while reca-
pitulating some anatomic and behavioral aspects of human AD, do
not appear to consistently model the strong transcriptional influ-
ence observed in human AD.
2. Materials and methods
2.1. Criteria for selection
Published transcriptional profile data were selected for analy-
sis based on availability in the Gene Expression Omnibus, having
young adult/control and aging/AD observations, being performed
on an Affymetrix detection platform, having complete transcrip-
tional profiles for each relevant subject available, and at least
two published studies within a species. Twenty-six transcriptional
profiles fulfilled these criteria. Two additional profiles using the
Affymetrix platform, but providing signal intensity data as supple-
mental files rather than in GEO were also selected. One data set
using RNA-seq instead of microarray technology, was also selected.
In total, 29 transcriptional profiles were used.
2.2. Reannotation and re-analysis of original data
Within each data set, control and AD,  or young and aged,
subjects’ transcriptional data were selected for analysis. Where
original .cel files were available (23/29 profiles), data were re-
analyzed using the RMA  probe level algorithm [35] (RMAexpress
with median polish, and quantile normalization). Profiles where
original signal intensity values were used are noted (Table 1).
Within each profile, heteroschedastic unpaired t-tests and log2 fold
changes were calculated for young vs aging or control vs AD. T-
tests here replaced correlation tests reported in prior work [21,26]
and analysis was restricted to the subset of transcriptional profiles
that are relevant to young vs aged, or to control vs AD [15–17,28]
conditions.
Annotated gene symbols were used to align results across stud-
ies/species. Analysis was  restricted to gene symbols homologous
between mouse and human genomes as defined by the human
and mouse homology data set from the Mouse Genome Database
(MGD- Feb. 2016), and official gene symbols according to the HUGO
Gene Nomenclature committee were used. P-value and fold change
results for all studies were combined in a single workbook (Supple-
mental File 1) with two worksheets- one for aging, and one for AD.
For transcriptional profiles where a gene was annotated on more
than one row, the row with the largest average signal intensity
across all subjects was reported.
2.3. Comparison across studies
Genes found to be significant across studies were assessed at
by% directional agreement, correlation across studies for significant
genes’ magnitudes of change (Pearson’s test), and numerically by
comparing the number of genes observed in the overlap vs. number
of genes expected.
2.3.1. Method 1
The number of genes expected in the overlap (∩) is convention-
ally estimated by multiplying the product of the p-value cutoffs ()
in the compared studies by the number of total genes (T) tested.
For example, if two  studies had 10,000 total genes in common, and
both used a 0.01 p-value cutoff, then 0.01 × 0.01 × 10000 = 1 gene
expected in the overlap; ∩ = T * 2. For all comparisons, Method 1
was set to produce ≤1 gene in the overlap. However, this approach
predicts the number of genes expected in the overlap if both studies
cortex profile, 162 genes were significantly downregulated and 219 were significantly upregulated. Therefore, the number of genes predicted to be significant and to agree
in  direction for both studies is [downregulated: (358/13146) * (162/13146) * 13146 = ∼4] + [upregulated: (962/13146) * (219/13146) = ∼16] = 20. Observed gives the values
found in the actual comparison. phFCR- post hoc False Concordance Rate- an extension of the False Discovery Rate assessment used in single transcriptional profile studies
(Method  2 overlap/observed overlap). B. A representative example of relative agreement across brain regions within subjects. For the 85 aging-significant genes overlapping
between hippocampus and EC, log 2 fold changes for entorhinal cortex are plotted against hippocampus. The observed number of genes, the post hoc false concordance rate
(phFCR), and percent agreement (%: based on direction of change) are shown.
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Table 1
Individual study characteristics.
Aging GSE# Reg Platform Ages Yng Age FDR
Human
[21] 11882 HIP HG-U133 plus2 20–59 vs 60–99 yr 8/10 12/13 0.10
EC  HG-U133 plus2 20–59 vs 60–99 yr 9/12 9/9 0.35
1[22] 1572 FC HG-U95Av2 26–56 vs. 61–106 yr 9/6 9/6 0.23
2[23] 46193 EC HG-U133A 33–55 vs 57–84 yr 2/2 2/2 0.21
DG  HG-U133A 33–55 vs 57–84 yr 2/2 2/2 0.14
*[24] 71620 PFC (BA11) Gene 1.1ST 20–59 vs 60–91 yr 116/25 36/13 0.04
PFC  (BA47) Gene 1.1ST 20–59 vs 60–91 yr 0.04
Rat
[15] 9990 HP RAE230A 3 vs 23mo 9/0 13/0 0.12
[16] 5666 HP RAE230A NT:5 vs 25mo 10/0 10/0 0.29
[17] 854 HP RG U34A 4 vs 24mo 9/0 10/0 0.24
1[18] 4821 DG RAE 230A 3 vs 24mo 27/0 53/0 0.33
Mouse
[19] 13120 CTX Mouse 430 2 5 vs 30mo 5/0 5/0 0.04
2[20] 5078 HIP MG  U74Av2 2 vs 15mo 9/0 14/0 0.27
AD  Ctrl AD
Human
[25]- 28146 HIP HG-U133 Plus 2 65–101 yr 6/2 5/10 0.27
[26] 1297 HIP HG-U133A 65–101 yr 7/2 5/10 0.18
2[27] Sup. EC HG-U133A 33–98 yr 6 6 0.60
Data  DG HG-U133A 33–98 yr 6 6 1.04
[28] 48350 HIP HG-U133 Plus 2 69–99 yr 10/9 9/8 0.06
EC  HG-U133 Plus 2 69–99 yr 7/7 7/7 0.31
[29] 36980 HIP HuGene-1 0-st 55–105 yr 5/5 3/4 0.10
FC  HuGene-1 0-st 55–105 yr 9/9 7/8 0.23
[30] 5390 PFC HG-U133A 32–76 yr 7/1 3/4 0.05
Mouse
[31] J20 14499 HIP Mouse430 2 7 mo:  GFP/Sham 5 4 3.29
EC  Mouse430 2 WT vs GFP Tg 5 4 0.68
[32] Tg2576 36237 HIP Mouse430 2 4 mo:  Wt  vs Tg 8 8 0.85
FC  Mouse430 2 4 mo:  Wt  vs Tg 8 8 0.39
[29] 3xTg 36981 HIP MoGene-1 0-st 14 mo:  WT vs Tg 3/0 3/0 0.54
[33] 5xFAD 50521 HIP MoEx-1 0-st 14 mo:  WT vs Tg 0/3 0/3 0.43
3[34] CK-p25 65159 HIP Illumina HiSeq 2000 3 mo:  CK v p25 (6 wk) 3/0 3/0 0.13
Columns: GSE#- Gene Expression Omnibus accession identification number for raw data in referenced study; Reg- brain region (CTX- neocortex, DG- dentate gyrus, EC-
entorhinal cortex, FC- frontal cortex, HIP- hippocampus, PFC- prefrontal cortex). Ages- age ranges and treatments, if applicable, are included (NT- non-trained, GFP- green
fluorescent protein controls, WT-  wild type, Tg- transgenic). Numbers of individual transcriptional profiles from male/female subjects within each category (Young vs Aged, or
Control  vs AD) are listed. FDR- False Discovery Rate for number of significant results (ttest, p ≤ 0.01)/total number of genes available for statistical testing. All signal intensity
values  re-calculated using Robust Multichip Analysis (RMA) except superscripted: 1-dChip, 2- MAS5, 3- RNA-seq. *Subjects from the original publication age <20 yrs and/or
RNA  integrity number <7.0 were excluded from analysis. Studies: 15- Kadish et al., 2009; 16: Rowe et al., 2007; 17: Blalock et al., 2003; 18: Burger et al., 2008; 19: Loerch
et  al., 2008; 20: Verbitsky et al., 2004; 21: Berchtold et al., 2008; 22: Lu et al., 2004; 23: Pavlopoulos et al., 2013; 24: Chen et al., 2016; 25: Blalock et al., 2011; 26- Blalock
et  al., 2004; 27: Small et al., 2005; 28: Berchtold et al., 2013; 29: Hokama et al., 2014; 30: Lockstone et al., 2013; 31: Nagahara et al., 2009; 32: Kleiman et al., 2010; 33- Paesler
et  al., 2015; 34: Gjoneska et al., 2016.
consist entirely of false positives, an unlikely event for published
work that has, a priori to this analysis, been reported to have a
greater-than-expected-by-chance number of significant genes.
2.3.2. Method 2- post hoc false concordance rate (phFCR)
A second numerical assessment method was devised to provide
a baseline estimate of the degree of overlapping and direction-
ally agreeing genes between two profiles if those profiles are not
related to one another, but do contain larger than expected-by-
chance numbers of significant genes. The method establishes the
probability (P) for randomly drawing a significant up- or down-
regulated gene from a transcriptional profile as the proportion of
the study’s total genes (T) that are significant (S) at a given p-value
cutoff in a given direction (P = S/T). Then, the likelihood of finding a
gene in the overlap between two profiles (1 and 2) is estimated by
P1 *P2, and the number of genes expected in the intersection is P1
* P2 * T. The number of genes expected to both overlap and agree in
direction of change by Method 2 forms the estimate of the number
of genes expected to show agreement by chance.
Method 2′s estimate, divided by the number of genes actually
observed to agree in the overlap, forms a modified False Discov-
ery Rate type of metric referred to here as the post hoc false
concordance rate (phFCR- post hoc because it is performed after
significance within each compared profile is already known, false
because it is predicting results if there is no biological relationship,
and concordance because it is evaluating agreement). The result-
ing number intersecting genes serves as an estimate of the number
of genes one would expect to find to agree in the intersection by
chance if two transcriptional profiles showed statistically power-
ful, but unrelated, effects on gene expression. phFCR values closer
to 0 indicate strong concordance, values closer to 1 indicate lack
of concordance. Interestingly, values greater than 1 may  indicate
discordant, or opposing, transcriptional profiles.
2.3.3. Transparency, rigor and reproducibility
All transcriptional profiles are available at the Gene Expression
Omnibus or as Supplemental files in their parent publications (ref-
erenced in Table 1) and the descriptions of procedures are intended
to allow others to reproduce this series of analyses from the raw
data. Age and sex are noted where available in the original studies.
Further, complete re-annotated and re-analyzed p-value and log2
fold change results for all profiles are provided (Supplemental File
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Fig. 2. Similarity within subjects across brain regions. In addition to Berchtold et al., 2008 (see Fig. 1), the first four of eight additional studies examining transcriptional
profiles  in the same subjects across >1 brain region are shown. For each comparison, the fold change (log2) for significant genes across regions are plotted, along with the
R2  value for the correlation. Within each graph, the observed number of genes, the post hoc false concordance rate (phFCR), and percent agreement (%: based on direction
of  change) are shown. A1–A2: Human aging. B1–B2: Human Alzheimer’s disease. In B1, Laser Capture Microdissected (LCM) formalin fixed paraffin embedded CA region of
the  hippocampus (2011) is contrasted with hand-dissected fresh frozen samples (2004).
1). Upon request, individual Excel workbooks with complete signal
intensity and annotation data for each profile’s re-analysis can be
provided.
3. Results
3.1. Individual study re-analysis
Table 1 lists characteristics for each of the stud-
ies/transcriptional profiles included in the analysis. Based on
re-annotated, analyzed and filtered data, false discovery rates
(FDRs) for each study are included.
3.2. Similarity across brain regions within subjects
Procedures for assessing concordance for the aging signature
across two  brain regions in one set of human subjects (Fig. 1A) are
shown. Based on 20 genes expected to agree in direction within
the overlap by chance (Method 2) vs 85 genes observed, a phFCR
of 0.24 (20/85) is calculated. The intersection of significant genes
is tested for percent agreement (100%) and strength of correlation
for fold changes (R2 = 0.92) across the two  studies (Fig. 1B). Within
subject cross-regional correlations were performed as in Fig. 1 for
all studies in which multiple regions were measured (Fig. 2).
For aging results (Fig. 1B and Fig. 2A1–2), all studies showed
strong cross-regional agreement among significant genes. For
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Fig. 3. Similarity within subjects across brain regions. In addition to Berchtold et al., 2008 (see Fig. 1), the second four of eight studies examining transcriptional profiles in
the  same subjects across >1 brain region are shown. For each comparison, the fold change (log2) for significant genes across regions are plotted, along with the R2 value for
the  correlation. Within each graph, the observed number of genes, the post hoc false concordance rate (phFCR), and percent agreement (%: based on direction of change) are
shown.  A1–A2: Human Alzheimer’s disease. B1–B2: Transgenic mouse models of Alzheimer’s disease.
human AD (Fig. 2B1–2 and Fig. 3A1–2), there was again a strong
cross-regional agreement within studies. Blalock et al. [26] and
Blalock et al. [25] (Fig. 2B1) show good agreement (51/53) but mod-
erate correlation. Although the same subjects were profiled in this
comparison, it is unique among these contrasts as contralateral
hippocampi were used, and one study Blalock et al. [26] used fresh-
frozen, hand-dissected tissue, while the other Blalock et al. [25]
used laser-capture microdissected hippocampal gray matter from
formalin-fixed, paraffin embedded specimens. The strongest agree-
ments were found across regions in human AD (Fig. 2B1–2, 3A1–2).
Despite having fewer overlapping significant genes across regions,
mouse models of AD (Fig. 3B1–2) still showed good agreement.
3.3. Aging within species
For human studies, the hippocampal profile from Berchtold et al.
[21] was  selected because of the statistical strength of its findings
(FDR = 0.1, Table 1) and balanced representation across the sexes.
As reported in the authors’ original study Berchtold et al. [21], there
is a sexually dimorphic effect on the brain aging transcriptome, but
because other studies either did not annotate, or did not evaluate,
this effect, transcriptional responses were assessed here without
separating the sexes. A similar rationale holds for not contrast-
ing time-of-death effects, which are significant as reported in Chen
et al. [24], but are not annotated in other studies.
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Fig. 4. Brain aging profile similarity within humans. Log2 fold changes are plotted for overlapping significant genes in each pairwise study comparison A1–4. Within each
graph, number of genes observed (Obs), post hoc false concordance rate (FCR), and percent agreement are shown.
Pairwise contrasts results from each of the other human stud-
ies are shown (Fig. 4A1–4). One profile, BA47 from Chen et al. [24],
is not graphed because of redundancy with the compared profile
BA11 (Fig. 4A4). Overall, % agreement, phFCRs, and correlations
all suggest agreement across studies/labs/and measurement plat-
forms for human aging. Similar robust agreement was observed
among rat studies (Fig. 5A1–3). Only two mouse brain aging profiles
were available (Fig. 5B) and showed agreement driven exclu-
sively by concordant upregulated genes. The different brain regions
examined and age-points (see Tables 1–2 vs 15 month contrasted
with 5 vs 30 mo)  may  help to explain these differences. Overall,
there appears to be a disproportionate number of genes that are
concordant across studies with generally more prevalent upregu-
lated genes.
3.4. Concordant aging signatures
To evaluate whether brain aging showed agreement across mul-
tiple studies simultaneously, a multiple-study aging signature was
constructed. As a caveat, it is important to note that different
array detection systems detect different numbers of genes (e.g,
the HGU133A detects 4457 annotated genes, while the Gene 1.1ST
detects 12475), so comparing across multiple studies reduces the
total list of genes available for testing. Further, while comparison
across studies increases the likelihood that common results are
truly positive, it also increases the likelihood that truly significant
results will be missed (increased false negative rate). Here, the con-
cordant list is intended as a bellwether of changing gene expression,
rather than a comprehensive list of all gene expression changes.
To build the consensus human brain aging list, four human aging
transcriptional profiles were selected. If a study had profiles from
more than one brain region, then the profile with the lowest FDR
was selected to avoid disproportionate representation from single
subjects. Therefore, the hippocampal profile from Berchtold et al.
[21], the dentate gyrus from Pavlopoulos et al. [23], the frontal cor-
tex from Lu et al. [22] and the prefrontal cortex BA11 from Chen
et al. [24] were selected and filtered in parallel by p-value (relaxed
to p ≤ 0.05 to partially compensate for presumed false negative
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Fig. 5. Brain aging profile similarity within rodents. Log2 fold changes are plotted for overlapping significant genes in each study. A1–A3: Concordance evaluations for rat
brain  aging profiles. B: Concordance evaluation for mouse brain aging (note that aging in [20] was  2 v 15 months old, while in [19] they were 5 vs 30 months). Within each
graph,  number of genes observed (Obs), post hoc false concordance rate (FCR), and percent agreement are shown.
results). 40/42 genes agree in direction of change across all four
studies and (Fig. 6A1–2) with a small phFCR and all pairwise corre-
lation r values >0.7. This indicates these profiles identify a common
thread of age-related signaling across brain regions, laboratories,
and platforms of gene expression.
A similar analysis was undertaken to evaluate the rat brain
aging across the four available rat transcriptional profiles Kadish
et al.; Rowe et al.; Blalock et al.; Burger et al. [15–18]. Good (24/25)
directional agreement, a low phFCR and correlation r values >0.6
(Fig. 6B1–2) all suggest a concordant profile. Only a single gene,
GFAP, was commonly upregulated in both the human and rat
aging consensus lists. However, finding consensus lists across brain
regions is highly likely to filter out common aging changes localized
to a particular brain region.
To test whether similar brain regions show similar aging
profiles across species, a representative human hippocampal
Berchtold et al. [21] profile was  contrasted with rat profiles
(Fig. 7A–D). Across species, aging phFCRs were generally weaker
than those within species (Figs. 4–6) and agreement was predom-
inately among upregulated genes. A pathway overrepresentation
analysis (Table 2) of results from the comparison with the
largest number of genes (Fig. 7D), indicated prominent common
immune/inflammatory effects among upregulated genes in human
and rat hippocampus. Similar selection procedures applied to
human and rat entorhinal cortex profiles Pavlopoulos et al. [23]
and Burger et al. [18] produced results no better than expected by
chance (not shown).
3.5. AD signatures within human and animal models
For comparisons across human AD transcriptional profiles,
Berchtold et al. [28] was selected as the study with the highest pro-
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portion of significant genes for comparison against other profiles.
For comparison across studies, if a single study had more than one
profiled brain region, then the region with the highest proportion
of significant genes was selected (Fig. 8A1–3). For human AD, the
actual numbers of genes found in the overlap generally exceeded
those observed in aging studies, suggesting a more expansive, and
downregulated, transcriptional effect. Further, phFCRs were gen-
erally low, indicating good agreement. Surprisingly, no familial
AD cases with known genetic lesions have publically available
transcriptional profile data. However, Down’s syndrome is con-
sidered to have an amyloid precursor protein gene-dose effect
that promotes the likelihood of developing AD-like pathology.
The idiopathic human AD profile was contrasted with this pro-
file (Fig. 8A4). The phFCR was relatively greater than in idiopathic
comparisons with a larger number of disagreeing genes but still
showed relatively good directional agreement and a large number
of overlapping genes.
For animal models, the CK-p25 hippocampal results Gjoneska
et al. [34] have the greatest proportion of significant findings and
are used as a baseline for comparison against other mouse AD mod-
els (Fig. 9A1–4). For the J20 mouse model, evaluation should be
tempered- the parent study had a large FDR (Table 1) and may
not have sufficient statistical strength for a reasonable interpre-
tation. However, across all comparisons, mouse models showed
relatively weak agreement with one another except 5xFAD vs CK-
p25 (Fig. 9A4), where agreement was  almost exclusively among
up-regulated genes.
3.6. Concordant AD signatures
To build the consensus AD signatures, hippocampal profiles
were used as they were the most prevalently measured brain
region (9/11 studies) and the two studies Small et al.; Nagahara
et al. [27,31] with the lowest # significant concordant genes within
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Fig. 7. Comparison of human vs. rodent hippocampal aging. Log2 Fold changes are plotted for overlapping significant genes in human hippocampal aging vs. four aging
transcriptional profiles in rodents. A: Mouse hippocampal aging profile. B–D. Rat hippocampal aging profiles. Within each graph, estimated numbers of genes predicted to
be  found by method 1 (M1), method 2 (M2), number of genes observed (Obs) and false concordance rate (FCR) are shown.
Table 2
Pathway overrepresentation analysis for hippocampal aging in human and rat.
Commonly Upregulated # PValue
positive regulation of immune system process 19 1.67E-13
positive regulation of protein kinase cascade 11 5.03E-07
regulation of inflammatory response 08 1.61E-06
regulation of cell activation 10 6.74E-06
protein homodimerization activity 12 1.51E-05
regulation of adaptive immune response 06 6.22E-05
regulation of cell motion 09 1.04E-04
regulation of immune effector process 07 1.13E-04
regulation of leukocyte activation 08 2.56E-04
response to organic substance 16 3.16E-04
blood circulation 08 5.10E-04
tissue remodeling 05 8.28E-04
Commonly downregulated
Tricarboxylic acid cycle 03 6.8E-04
Left: Selected Gene Ontology categories significantly overrepresented by genes com-
monly upregulated in human [21] and rat [15] hippocampal aging. #: number of
significant genes in category. PValue-probability that number of genes would be
found in category by chance.
species (Fig. 8A3 and Fig. 9A1) were excluded. The human AD sig-
nature (Fig. 10A1) was  dominated by downregulated genes and
showed a low phFCR and strong all pairwise correlation among
fold changes (Fig. 10A2). Functional pathway overrepresentation
analyses for concordant genes (Fig. 10A3) revealed concordant
upregulated processes associated with cell–cell contact and possi-
bly blood-vessel related changes, while downregulated categories
showed a much stronger suppression of genes associated with
mitochondria and neuronal/synaptic processes. In stark contrast,
mouse transgenic AD models found no genes at the specified com-
mon  p-value cutoff of 0.05. For display purposes, the p-value was
relaxed to 0.2, but the resulting genes show very poor agreement
(Fig. 10B1), a phFCR >1, and weak all-pairwise correlations among
fold changes (Fig. 10B2).
3.7. Individual mouse models of AD vs. human AD
Because the mouse profiles are not concordant with one
another, it is possible that one mouse model does recapitulate
human AD while others do not. To test this, each brain region in each
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Fig. 8. Human AD similarity. Log2 fold changes are plotted for overlapping significant genes in each study, along with numerical comparison results. A1–3: Concordance
evaluations are made for human brain AD profiles. A4- comparison with human Down’s syndrome subjects (control Down’s vs. Down’s with AD-like pathology). Within each
graph, estimated numbers of genes predicted to be found by method 1 (M1), method 2 (M2), number of genes observed (Obs) and false concordance rate (FCR) are shown.
mouse model was contrasted with human AD (Fig. 11 and Fig. 12).
Although most mouse models showed very poor agreement (Fig. 11
and Fig. 12A) with phFCRs >1 and negative (albeit weak) correla-
tions, the 5xFAD and CK-p25 (Fig. 12B,C) models did show good
directional agreement and moderate correlation strength, particu-
larly among upregulated genes.
3.8. Summarized assessment of concordance
For each of the comparisons (across region within subject,
within human aging, within rodent aging, aging across humans
and rodents, within human AD, within mouse model AD, and
AD in human vs mouse) the three concordance measures (%
agreement, fold change correlation, and phFCR) were averaged
and plotted (Fig. 13A–C). Results were contrasted with the pre-
dicted values for random chance using one-sample t-tests and
in all comparisons, with the exception of transgenic mouse and
AD in Human vs Mouse, were significantly better than chance
for all concordance measures. By rank: across region > Rat Brain
Aging > Human Brain Aging > Aging in Human vs Rodent > AD in
Human vs Mouse > Transgenic Mouse.
4. Discussion
To our knowledge, this is the first study to provide a statis-
tical assessment of replicability across multiple published brain
aging and Alzheimer’s disease transcriptional studies in human
and rodent models. Assessment of similarity/reproducibility across
studies is often limited because measures of central tendency and
variance are reported (sometimes only graphically), and often with
limited description of the procedures used to produce those mea-
sures, as well as bias towards reporting significant findings [10,11].
Although transcriptional profiling is sometimes maligned for mul-
tiple testing error propensity, and for measuring an intermediate
molecular species that may  be less relevant to biology than pro-
tein, transcriptional profiling data does offer certain advantages.
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Fig. 9. Similarity among AD mouse models. Log2 fold changes are plotted for overlapping significant genes in each study, along with numerical comparison results. A1–A4:
Concordance evaluations for transgenic mouse models of AD. Within each graph, estimated numbers of genes predicted to be found by method 1 (M1), method 2 (M2),
number of genes observed (Obs) and false concordance rate (FCR) are shown.
First, measures are less biased because a large proportion of the bio-
logical output for an entire class of molecules (the transcriptome),
rather than a narrow subset of researcher-selected components, is
measured. Second, raw data for all observations in each subject are
often available in publically accessible databases. Third, detailed
descriptions of the methods used in the original (‘parent’) publica-
tions, and, in most cases, thorough annotations for each subject, are
provided. Together, this availability engenders the ability to test for
agreement across different preparations purporting to measure the
same phenomenon.
Key findings here include brain aging’s consistent transcrip-
tional profile across human [21–24] and rodent [15–18] studies.
Within the hippocampus, this concordant profile has a strong
upregulation of immune/inflammatory signaling. Further, the tran-
scriptional profile for human idiopathic Alzheimer’s disease is also
robust across studies [26–29], but unlike aging, largely focuses on
downregulation of neuronal and mitochondrial genes. It is impor-
tant to note that, in human AD studies, normal aged subjects are
contrasted with similarly aged AD subjects. Because human aging
does show a consistent immune-inflammatory signature [36–39],
it is likely that the robust human AD signatures identified here
are manifested on a background of increased age-related immune-
inflammatory signaling, a feature that likely was not present in
the (younger) AD mouse models. Mice that model the age-related
changes in brain immune signaling may  provide important data
on selective, age-related mechanisms for the establishment and
spread of AD-related pathology.
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Fig. 10. Alzheimer’s disease human and animal model gene signatures. A1: Heatmap of ranked fold changes from most negative (blue) to most positive (red) are shown for
genes  significantly changed (p ≤ 0.05) in three human hippocampal brain AD studies. For display purposes, the top 10% commonly upregulated and downregulated genes are
shown  out of 503 total genes (491 of which agreed in direction across all studies). A2: Correlation matrix r-values from Pearson’s test for all pairwise comparisons among
the  commonly significant human hippocampal AD genes. A3: Pathway overrepresentation analysis results with pathway, number of genes significant in pathway (#), and
probability such a result would be found by chance (Pvalue). B1: Heatmap of ranked fold changes for mouse transgenic AD model genes significant across four studies at
p  ≤ 0.05. Two genes (CAPG and IGSF6) showed directional agreement. One gene, IL18 was consistent in hippocampal specimens, but not in DG. B2: Correlation matrix r values
(Pearson’s test) for all pairwise comparisons among the commonly significant transgenic mouse model AD genes. Within each correlation matrix (A2), estimated numbers
of  genes predicted to be found by method 1 (M1), method 2 (M2), number of genes observed (Obs) and false concordance rate (FCR) are shown (For interpretation of the
references to colour in this figure legend, the reader is referred to the web  version of this article.).
Three transgenic mouse models of AD (J20, Tg2576, 3xTg)
[29,31,32] showed poor concordance with each other as well as
with human AD. Further, genes commonly regulated in human AD
and these three mouse models often showed opposing directions of
change. This discordant effect suggests the interesting speculation
that some model mice, introduced to a human genetic pathology,
may  generate an opposing and potentially compensatory response.
If so, then some of these opposing changes may  represent rea-
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Fig. 11. Comparison of human AD transcriptional profile with individual mouse models and brain regions. Log2 fold changes for genes found significant across human and
individual mouse transgenic AD models and regions (first 4 of 7 comparisons) are shown. A1–2: Hippocampal (Hip) and entorhinal cortex (EC) from the J20 mouse. B1–B2:
Hippocampal and frontal cortex (F. Ctx) from the Tg2576 mouse). Within each graph, estimated numbers of genes predicted to be found by method 1 (M1), method 2 (M2),
number of genes observed (Obs) and false concordance rate (FCR) are shown.
sonable therapeutic targets for human studies [40,41]. The 5xFAD,
and CK-p25 mice generally showed better agreement with human
AD. However, this agreement was centered on upregulated, rather
than down-regulated genes, indicating a failure to model the most
consistent and prominent transcriptional signature of human idio-
pathic AD. This is of considerable note, as these models have
well-reported neurodegenerative effects [42,43]. Although the CK-
p25′s neurodegenerative effects may, at least in part, be mediated
by neurotoxicity of the tetracycline transactivator required to
induce the model [44]. If so, then this neurotoxic transcriptional
signature does not manifest with the same downward deflection of
synaptic and mitochondrial genes seen in human AD. Differences
in numbers of subjects, background strains, age ranges and sex
(Table 1) may  also contribute to lack of agreement across transgenic
AD mouse models.
Interestingly, the human studies used here represent the most
common, idiopathic form of AD, while the animal models (with
the exception of CK-p25) are based on genetic lesions associated
with familial AD. If the mice are modeling familial AD, then this
would also infer that familial AD is distinct from idiopathic AD at the
transcriptional level. It would be preferable to test for this relation-
ship by contrasting the transgenic mouse profiles with the profiles
of subjects in whom the genetic lesion was  originally identified.
However, no such human familial AD brain transcriptional profiles
have become available. Instead, we used a published Down’s syn-
drome transcriptional study (Down’s cases without AD pathology
were used as control) [30] as an approximation. Down’s subjects are
thought to develop AD-like pathology through a genetic effect sim-
ilar to familial AD. The Down’s cases shared moderate concordance
with idiopathic AD, including a large block of downregulated genes,
suggesting that genetic AD in humans shares more similarity with
idiopathic cases than with mouse models. Alternatively, analysis of
more recently developed animal models of late onset Alzheimer’s
disease [45–48] that appreciate chronic age-related changes [49]
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Fig. 12. Comparison of human AD transcriptional profile with individual mouse models and brain regions. Log2 fold changes for genes found significant across human and
individual mouse transgenic AD models (last 3 of 7) are shown. A: Hippocampus from the 3xTg mouse. B. Hippocampus from the 5xFAD mouse. C: Hippocampus from the
CK-p25 inducible mouse model (RNA-seq based fold changes). Within each graph, estimated numbers of genes predicted to be found by method 1 (M1), method 2 (M2),
number  of genes observed (Obs) and false concordance rate (FCR) are shown.
may  importantly shed light on molecular processes associated with
the development of idiopathic AD.
Within-subject, across brain region comparisons show highly
concordant signatures regardless of species or condition. On the
one hand, aging and/or AD could have generalized transcriptional
effects spanning brain regions. On the other hand, subject selec-
tion from the population may  strongly influence gene expression.
If the latter is true, then comparisons in which multiple regions
from single subjects are used to confirm findings may  be less use-
ful than comparisons across different sets of subjects. It should be
noted that the samples used for these analyses are region-selective
homogenate brain preparations. As transcriptional profiling from
cell-type and sub-region [25,50–54] specific preparations become
more prevalent, analyses of these more defined areas may  help to
further elucidate the relationships between human conditions and
animals intended to model them.
To assess concordance across studies, selection criteria were set
so that ≤1 gene would be identified by chance in the overlap if all
significant results in both comparisons were false positives. Then,
three measures were used to determine concordance among over-
lapping genes: percent agreement in direction of change among
significant genes; correlation in magnitude of change among sig-
nificant genes; and a post hoc false concordance rate (phFCR).
Although the first two  measures are straight forward, the third was
developed during the course of this analysis and is a modification
of the popular False Discovery Rate (FDR) calculated for individual
studies [55]. The FDR calculates the proportion of genes expected
to be found significant at a given p-value cutoff for a given total
list size of genes. Smaller FDRs indicate more reliable results, while
FDRs closer to 1 represent results that are no better than chance.
Similarly, the phFCR first calculates the proportions of genes found
to be up or down regulated in each comparison study, and then
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Fig. 13. Consolidated comparisons. Averaged pairwise contrast comparison results for direction of change (A), correlation (B), and post hoc False Concordance Rate (C) are
shown. Across Regions from Figs. 1B, 2 and 3; Human Brain Aging from Fig. 4; Rat Brain Aging from Fig. 5; Aging in Human vs. Rodent from Fig. 7; Human AD from Fig. 8;
Transgenic Mouse from Fig. 10; and AD in Human vs. Mouse from Figs. 11 and 12. * p ≤ 0.05; one-sample t-test vs. chance (dashed green line) (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.).
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calculates the number of genes expected to be both statistically
significant and to agree in direction of change across the studies.
This ‘false concordance’ estimate is then divided by the number of
genes actually found to create the phFCR.
The phFCR, or some similar measure, could be used in evaluat-
ing similarity across massively parallel analyses, like transcriptome
studies, to protect against over-interpreting chance levels of con-
cordance. Additionally, the FDR (Table 1) provides an assessment
of individual study statistical reliability. In comparisons where the
FDR is high in at least one of the studies, interpretations from con-
cordance analysis should be tempered as the genes being compared
are not exceeding chance discovery at the individual study level.
Finally, this comparison procedure is reductive- a single anomalous
study folded in with other, more reliable studies, will disrupt their
otherwise strong findings. Similarly, a statistically low-powered
study will likely miss more subtle gene expression changes. Even
among studies with consistent findings, filtering results across
studies reduces the list size, and as confidence increases that indi-
vidual results found in the overlap are indeed truly positive, so
too does confidence that other, true positives, are being missed.
Therefore, the overlapping genes are reasonable for establishing
similarity across studies, but are unlikely to capture the full spec-
trum of truly positive results.
5. Conclusions
Transcriptional profiles of brain aging are concordant across
rodents and humans in multiple brain regions. The hippocampal
aging profiles in humans and rats show strong upregulation of
immune/inflammatory signaling. There is a high degree of con-
cordance within the transcriptional profiles of human AD that is
primarily centered on downregulated neuronal and mitochondrial
signals. This signature may  reflect neurodegenerative processes in
idiopathic AD. Among five transgenic mouse models, three (J20,
Tg2576, 3xFAD) show poor concordance with each other as well
as with human AD. Two (5xFAD and CK-p25) show moderate
agreement with one another and with human AD, although this
agreement is primarily centered on upregulated genes. Because
aging shows a clear shift in gene expression, one method for more
fully aligning AD models with the human condition would be estab-
lishing pathology in animals at an age that is model-consistent with
the age of onset for AD in humans.
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